Kaan Kavakli

List of Publications by Year
in descending order

65	1,530	361413	330143
papers	citations	20 h-index	37 g-index

65	65	65	1300
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	27.0	414
2	Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood, 2019, 134, 1973-1982.	1.4	103
3	Prophylaxis vs. onâ€demand treatment with BAY 81â€8973, a fullâ€length plasma proteinâ€free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis, 2015, 13, 360-369.	3.8	74
4	Long-term evaluation of radioisotope synovectomy with Yttrium 90 for chronic synovitis in Turkish haemophiliacs: Izmir experience. Haemophilia, 2006, 12, 28-35.	2.1	57
5	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307.	2.5	56
6	A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. Journal of Thrombosis and Haemostasis, 2018, 16, 2184-2195.	3.8	56
7	Prospective Evaluation of Whole Genome MicroRNA Expression Profiling in Childhood Acute Lymphoblastic Leukemia. BioMed Research International, 2014, 2014, 1-7.	1.9	54
8	Onceâ€weekly prophylactic treatment vs. onâ€demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia, 2016, 22, 381-388.	2.1	41
9	Radioisotope synovectomy with rhenium186in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia, 2008, 14, 518-523.	2.1	40
10	Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia, 2010, 16, 902-909.	2.1	33
11	Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data. Haemophilia, 2019, 25, 60-66.	2.1	32
12	Inhibitors to factor <scp>VII</scp> in congenital factor <scp>VII</scp> deficiency. Haemophilia, 2014, 20, e188-91.	2.1	27
13	Circumcision and Haemophilia: a perspective. Haemophilia, 1998, 4, 1-3.	2.1	26
14	Fibrin glue and clinical impact on haemophilia care. Haemophilia, 1999, 5, 392-396.	2.1	25
15	SHOULD HEMOPHILIAC PATIENTS BE CIRCUMCISED?. Pediatric Hematology and Oncology, 2000, 17, 149-153.	0.8	25
16	Efficacy, safety and pharmacokinetics of a new highâ€purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia, 2016, 22, 419-425.	2.1	25
17	Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia, 1998, 4, 104-108.	2.1	24
18	Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. Journal of Thrombosis and Haemostasis, 2020, 18, 815-824.	3.8	24

#	Article	IF	Citations
19	The value of early treatment in patients with haemophilia and inhibitors. Haemophilia, 2010, 16, 487-494.	2.1	23
20	PLASMA LEVELS OF THE VON WILLEBRAND FACTOR-CLEAVING PROTEASE IN PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS IN CHILDREN. Pediatric Hematology and Oncology, 2002, 19, 467-473.	0.8	22
21	A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. Journal of Medical Economics, 2005, 8, 46-54.	2.1	20
22	Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey. Haemophilia, 2012, 18, 383-391.	2.1	20
23	Serum Erythropoietin Levels in Patients with Beta Thalassemia Major and Intermedia. Pediatric Hematology and Oncology, 1997, 14, 161-167.	0.8	19
24	Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion, 2018, 58, 413-422.	1.6	19
25	NEUROPSYCHOLOGIC SEQUELAE IN THE LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. Pediatric Hematology and Oncology, 1999, 16, 213-220.	0.8	18
26	Current view and outcome of ITI therapy - A change over time?. Thrombosis Research, 2016, 148, 38-44.	1.7	18
27	Pharmacokinetics of a highâ€purity plasmaâ€derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. Haemophilia, 2016, 22, 426-432.	2.1	17
28	Common themes and challenges in hemophilia care: a multinational perspective. Hematology, 2019, 24, 39-48.	1.5	17
29	Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia, 2020, 26, 64-72.	2.1	17
30	The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.1	16
31	Longâ€term evaluation of chromosomal breakages after radioisotope synovectomy for treatment of target joints in patients with haemophilia. Haemophilia, 2010, 16, 474-478.	2.1	15
32	Longâ€term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia, 2018, 24, e391-e394.	2.1	15
33	The impact of psychosocial determinants on caregiversâ€™ burden of children with haemophilia (results) Tj ETQq1 1 0.784314 rgBT /	2.1	13
34	Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study. Blood, 2010, 116, 720-720.	1.4	13
35	RARE COAGULATION DISORDERS. Retrospective analyses of 156 patients in TURKEY. Turkish Journal of Haematology, 2012, 29, 48-54.	0.5	11
36	Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia, 2017, 23, 255-263.	2.1	9

#	Article	IF	Citations
37	Factor 8 Gene Mutation Spectrum of 270 Patients with Haemophilia A: Identification of 36 Novel Mutations. Turkish Journal of Haematology, 2020, 37, 145-153.	0.5	9
38	Beta-Thalassemia Alleles in Aegean Region of Turkey: Effect on Clinical Severity of Disease. Pediatric Hematology and Oncology, 1997, 14, 59-65.	0.8	8
39	Safer and much cheaper circumcision using fibrin glue in severe haemophilia. Haemophilia, 1997, 3, 209-211.	2.1	8
40	Intron 22 inversions in the Turkish haemophilia A patients: prevalence and haplotype analysis. Haemophilia, 1999, 5, 169-173.	2.1	7
41	Micronucleus evaluation for determining the chromosomal breakages after radionuclide synovectomy in patients with hemophilia. Annals of Nuclear Medicine, 2012, 26, 41-46.	2.2	7
42	Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency. Blood Coagulation and Fibrinolysis, 2019, 30, 34-41.	1.0	7
43	Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Reviews, 2021, 50, 100833.	5.7	6
44	Clinical experience with moroctocog alfa (<scp>AF</scp>â€<scp>CC</scp>) in younger paediatric patients with severe haemophilia A: Two openâ€label studies. Haemophilia, 2018, 24, 604-610.	2.1	5
45	Impact of the HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study. Turkish Journal of Haematology, 2021, 38, 101-110.	0.5	5
46	Brief report. Plasma interleukin-3 (IL-3) and IL-7 concentrations in children with homozygous beta-thalassemia. Journal of Tropical Pediatrics, 1997, 43, 366-367.	1.5	4
47	Cost of hemophilia A in Turkey: an economic disease burden analysis. Journal of Medical Economics, 2021, 24, 1052-1059.	2.1	4
48	A patient with WT syndrome and Castleman disease. Pediatrics International, 1995, 37, 108-112.	0.5	3
49	Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease. Haemophilia, 2001, 7, 482-489.	2.1	3
50	Termination of Transfusion Dependence in /J-Thalassemia: Two-Year Experience with Recombinant Human Erythropoietin. Pediatric Hematology and Oncology, 1997, 14, 285-287.	0.8	2
51	Safety and effectiveness of room temperature stable recombinant factor <scp>VII</scp>a in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. Haemophilia, 2017, 23, 575-582.	2.1	2
52	Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors. Blood, 2010, 116, 719-719.	1.4	2
53	Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study. Turkish Journal of Haematology, 2018, 35, 129-133.	0.5	2
54	Specific Antibody Response in Children with Thalassemia Major. Pediatric Hematology and Oncology, 1997, 14, 181-183.	0.8	1

#	Article	IF	Citations
55	Letter to the Editor: TREATMENT OF IRON-DEFICIENCY ANEMIA AND ERYTHROCYTE CATALASE ACTIVITY. Pediatric Hematology and Oncology, 2005, 22, 647-648.	0.8	1
56	Real-World Early Treatment with Room Temperatureâ€“Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7â„¢ Post Hoc Analyses. TH Open, 2017, 01, e130-e138.	1.4	1
57	Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset. Blood Coagulation and Fibrinolysis, 2021, 32, 180-185.	1.0	1
58	Radioisotope Synovectomy for Treating Chronic Synovitis in Inhibitor Patients with Hemophilia.. Blood, 2006, 108, 4005-4005.	1.4	1
59	Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B. Blood, 2014, 124, 1523-1523.	1.4	1
60	Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7â„¢ Study. Blood, 2016, 128, 1439-1439.	1.4	1
61	New Treatment Modalities in Hemophilia. Trends in Pediatrics, 2022, 3, 1-4.	0.1	1
62	Haemophilia clinical care and research needs: Assessing priorities. Haemophilia, 2018, 24, e270-e273.	2.1	0
63	A Novel Molecular Indicator for Inhibitor Development in Haemophilia A. Journal of Pediatric Research, 2021, 8, 102-109.	0.2	0
64	Management of the Sponataneous Bleeding Episodes in Factor VII Deficiency. A Prospective Evaluation of the STER,. Blood, 2011, 118, 3368-3368.	1.4	0
65	Retrospective Evaluation of Childhood Cutaneous Mastocytosis Cases. Journal of Pediatric Research, 2020, 7, 13-17.	0.2	0